# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Epstein Barr Virus, Chronic

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 20 results.
Genetic Studies of Chronic Active Epstein-Barr Disease
Status: Recruiting
Last Changed: Apr 02, 2020
First Received: Mar 25, 2002
Disease(s): Chronic Active Epstein-Barr Virus
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO): a Phase 2 Randomised Control Trial
Status: Recruiting
Last Changed: May 21, 2019
First Received: Oct 09, 2018
Disease(s): COPD, EBV
Intervention(s): Valaciclovir, Placebo capsules (containing Avicel blend)
Locations: Belfast Health and Social Care Trust, Belfast, Down, United Kingdom
PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV
Status: Recruiting
Last Changed: Feb 11, 2020
First Received: Sep 10, 2019
Disease(s): EBV Infection
Intervention(s): PD1 antibody, lenalidomide
Locations: Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection
Status: Recruiting
Last Changed: Mar 10, 2020
First Received: Apr 09, 2018
Disease(s): EBV Infection
Intervention(s): peripheral EBV-DNA load
Locations: Tongji hospital, Tongji medical collage of HUST, Wuhan, Hubei, China
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia
Status: Recruiting
Last Changed: Apr 03, 2020
First Received: Jun 03, 2014
Disease(s): Post-transplant Lymphoproliferative Disorder, B-Cell Prolymphocytic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Recurrent Lymphoplasmacytic Lymphoma
Intervention(s): cyclophosphamide, laboratory biomarker analysis, Bendamustine Hydrochloride, Etoposide, Fludarabine Phosphate, Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Locations: City of Hope Medical Center, Duarte, California, United States
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
Status: Recruiting
Last Changed: Jan 28, 2020
First Received: Nov 10, 2014
Disease(s): Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus, T/NK-lymphoproliferative Disease, Nasopharyngeal Carcinoma, Smooth Muscle Tumor
Intervention(s): MABEL CTLs, Cyclophosphamide, Fludarabine
Locations: Houston Methodist Hospital, Houston, Texas, United States
Texas Children's Hospital, Houston, Texas, United States
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Status: Recruiting
Last Changed: Sep 25, 2019
First Received: Oct 14, 2013
Disease(s): Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelofibrosis, Myelodysplasia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma
Intervention(s): Fludarabine, Cyclophosphamide, Total Body Irradiation, Cyclosporine A, Mycophenylate mofetil, Umbilical cord blood
Locations: University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
Status: Recruiting
Last Changed: Nov 21, 2019
First Received: Jan 04, 2013
Disease(s): Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Juvenile Myelomonocytic Leukemia, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Polycythemia Vera, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Cytopenia With Multilineage Dysplasia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
Intervention(s): Fludarabine phosphate, Thiotepa, Total body irradiation, Therapeutic allogeneic lymphocytes, Cyclophosphamide, Allogeneic hematopoietic stem cell transplantation (HSCT), Peripheral blood stem cell transplantation, Tacrolimus, Mycophenolate mofetil
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Status: Not yet recruiting
Last Changed: Mar 04, 2020
First Received: Dec 12, 2019
Disease(s): Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult Diffuse Large Cell Lymphoma, Anaplastic Large Cell Lymphoma, Burkitt Lymphoma, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma
Intervention(s): Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine, Filgrastim, Fludarabine, Mycophenolate Mofetil, Mycophenolate Sodium, Total-Body Irradiation, Treosulfan
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Phase I CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Adults With Recurrent/Refractory B Cell Malignancies
Status: Recruiting
Last Changed: Aug 29, 2019
First Received: Jul 31, 2017
Disease(s): B Acute Lymphoblastic Leukemia, CD19 Positive, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma of the Elderly, Minimal Residual Disease, Philadelphia Chromosome Positive, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Intervention(s): Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Questionnaire Administration
Locations: Stanford University, School of Medicine, Palo Alto, California, United States